论文信息 - Osimertinib as first‐line treatment for EGFR mutation‐positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohorts: LBA1_PR - 字舞流文

Osimertinib as first‐line treatment for EGFR mutation‐positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohorts: LBA1_PR

P. Jänne | Y. Ohe | S. Ramalingam | Dong-Wan Kim | T. John | T. Kurata | N. Nogami | C. Lee | J. Yang | J. Yang | D. Kim | C. Lee